Biocare Copenhagen A/S Sustainability Profile
Biocare Copenhagen A/S, a leading name in the biotechnology sector, is headquartered in Denmark (DK) and operates extensively across Europe and beyond. Founded in 2005, the company has established itself as a pioneer in developing innovative biopharmaceutical solutions, focusing on areas such as immunology and oncology. Biocare's core offerings include advanced diagnostic tools and therapeutic products that leverage cutting-edge technology, setting them apart in a competitive market. With a commitment to quality and efficacy, the company has achieved significant milestones, including numerous regulatory approvals and partnerships with key industry players. Recognised for its expertise and innovation, Biocare Copenhagen A/S continues to strengthen its market position, contributing to advancements in healthcare and improving patient outcomes globally.
DitchCarbon Score
How does Biocare Copenhagen A/S's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Food Product Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biocare Copenhagen A/S's score of 87 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biocare Copenhagen A/S, headquartered in Denmark (DK), currently does not report specific carbon emissions data for the most recent year. The company is a current subsidiary of DSM-Firmenich AG, which influences its climate commitments and emissions reporting. As part of its corporate family relationship, Biocare Copenhagen A/S inherits climate initiatives and targets from DSM-Firmenich AG. This includes participation in various sustainability frameworks such as the Science Based Targets initiative (SBTi), CDP, and RE100, all of which are cascaded from DSM-Firmenich AG. However, specific reduction targets or achievements for Biocare Copenhagen A/S are not detailed. While no absolute emissions numbers are available, the company's alignment with DSM-Firmenich AG's sustainability efforts indicates a commitment to reducing carbon emissions and enhancing climate resilience. The absence of direct emissions data suggests that Biocare Copenhagen A/S is in the process of developing its own reporting and reduction strategies, guided by the overarching goals of its parent organisation.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 1,030,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 590,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 8,683,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - | 00,000,000,000 | 0,000,000,000 | 00,000,000,000 | 00,000,000,000 |
How Carbon Intensive is Biocare Copenhagen A/S's Industry?
How Carbon Intensive is Biocare Copenhagen A/S's Location?
Biocare Copenhagen A/S's Scope 3 Categories Breakdown
Biocare Copenhagen A/S's Scope 3 emissions, which increased by 7% last year and increased by approximately 28% since 2016, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 75% of Scope 3 emissions.
Top Scope 3 Categories
Biocare Copenhagen A/S's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Biocare Copenhagen A/S has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
